ST

Stephen Trusheim

Cofounder & CEO, Tome • Decoding Contracts

San Francisco, California

Invests in

Stages:

  • Min Investment:

    $5,000,000.00
  • Max Investment:

    $20,000,000.00
  • Target Investment:

    $12,500,000.00

Work Experience

2021

  • Cofounder & CEO

    2021

    Tome decodes contracts with generative AI. I cofounded Tome because I hate contracts, and I _really_ hate "contracting." We transform the opaque, mystical legal process into a transparent, empowering experience for everyone. Proudly backed by SignalFire, Quiet Capital, Moxxie Ventures, Uncommon Capital, Shrug Capital, 20+ angels, and at least one former Solicitor General.

  • Venture Partner

    2022

  • Partner & Head of Operations

    2015 - 2022

    SignalFire is what happens when AI nerds run a VC firm. We've built unique technology to source, accelerate, and empower exceptional founders. My review, as a founder: ⭐⭐⭐⭐⭐ As a Partner, I invested in AI, hybrid systems, and fintech (incl. blockchain tech!) As Head of Operations, I ran the back office of our Registered Investment Adviser from $0 to >$2B AUM. I executed >700 investments, raised 35 funds, and managed finance, audit, fundraising & legal. I also spent more than $25 million on lawyers. Read more: https://www.signalfire.com

2014 - 2014

  • Engineering

    2014 - 2014

    Engineered an API-first platform to (try to) make banking better. No dice. Acq, Silicon Valley Bank.

  • COO

    2010 - 2014

    Led ops & built full-stack fintech products at a $20M nonprofit financial services organization. Co-founded Cardinal Fund, the country's largest undergraduate endowment management program.

2012 - 2012

  • Engineering, Intel Architecture Group

    2012 - 2012

    Developed low-power, always-on sensor analytics integrated into Ultrabooks.

2010 - 2012

  • Principal

    2010 - 2012

    Employee #3, batches 1-4. Mentored entrepreneurs at the world's best student startup accelerator.

2007 - 2009

  • Software Engineer

    2007 - 2009

    Reduced healthcare-acquired infections with AI-targeted interventions, saving lives and money. Automated genetic testing with computer vision.